Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Research Report 2026(Status and Outlook)
Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size was estimated at USD 1847.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc
SOM Biotech
Johnson & Johnson Services, Inc.
AstraZeneca
Astellas Pharma, Inc.
BridgeBio Pharma, Inc.
Bristol-Myers Squibb Company
Acrotech Biopharma
Market Segmentation (by Type)
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others
Market Segmentation (by Application)
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
Overview of the regional outlook of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size was estimated at USD 1847.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.00% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc
SOM Biotech
Johnson & Johnson Services, Inc.
AstraZeneca
Astellas Pharma, Inc.
BridgeBio Pharma, Inc.
Bristol-Myers Squibb Company
Acrotech Biopharma
Market Segmentation (by Type)
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others
Market Segmentation (by Application)
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
Overview of the regional outlook of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
1.2 Key Market Segments
1.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Type
1.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Life Cycle
3.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Manufacturers (2020-2025)
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Manufacturers (2020-2025)
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Competitive Situation and Trends
3.8.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Rate
3.8.2 Global 5 and 10 Largest Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT INDUSTRY CHAIN ANALYSIS
4.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
5.7 ESG Ratings of Leading Companies
6 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2020-2025)
6.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2020-2025)
6.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price by Type (2020-2025)
7 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Sales by Application (2020-2025)
7.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Application (2020-2025)
7.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
8 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SALES BY REGION
8.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region
8.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.3 North America
8.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.5.2 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.6.2 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.7.2 Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET PRODUCTION BY REGION
9.1 Global Production of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Region(2020-2025)
9.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Region (2020-2025)
9.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production
9.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production
9.5.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.5.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (2020-2025)
9.6.1 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.6.2 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (2020-2025)
9.7.1 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.7.2 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Pfizer Inc
10.1.1 Pfizer Inc Basic Information
10.1.2 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.1.4 Pfizer Inc Business Overview
10.1.5 Pfizer Inc SWOT Analysis
10.1.6 Pfizer Inc Recent Developments
10.2 GlaxoSmithKline Plc
10.2.1 GlaxoSmithKline Plc Basic Information
10.2.2 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.2.4 GlaxoSmithKline Plc Business Overview
10.2.5 GlaxoSmithKline Plc SWOT Analysis
10.2.6 GlaxoSmithKline Plc Recent Developments
10.3 Eidos Therapeutics
10.3.1 Eidos Therapeutics Basic Information
10.3.2 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.3.4 Eidos Therapeutics Business Overview
10.3.5 Eidos Therapeutics SWOT Analysis
10.3.6 Eidos Therapeutics Recent Developments
10.4 Ionis Pharmaceuticals, Inc
10.4.1 Ionis Pharmaceuticals, Inc Basic Information
10.4.2 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.4.4 Ionis Pharmaceuticals, Inc Business Overview
10.4.5 Ionis Pharmaceuticals, Inc Recent Developments
10.5 Alnylam Pharmaceuticals
10.5.1 Alnylam Pharmaceuticals Basic Information
10.5.2 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.5.4 Alnylam Pharmaceuticals Business Overview
10.5.5 Alnylam Pharmaceuticals Recent Developments
10.6 Prothena Corporation Plc
10.6.1 Prothena Corporation Plc Basic Information
10.6.2 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.6.4 Prothena Corporation Plc Business Overview
10.6.5 Prothena Corporation Plc Recent Developments
10.7 Intellia Therapeutics, Inc
10.7.1 Intellia Therapeutics, Inc Basic Information
10.7.2 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.7.4 Intellia Therapeutics, Inc Business Overview
10.7.5 Intellia Therapeutics, Inc Recent Developments
10.8 Corino Therapeutics, Inc
10.8.1 Corino Therapeutics, Inc Basic Information
10.8.2 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.8.4 Corino Therapeutics, Inc Business Overview
10.8.5 Corino Therapeutics, Inc Recent Developments
10.9 SOM Biotech
10.9.1 SOM Biotech Basic Information
10.9.2 SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.9.3 SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.9.4 SOM Biotech Business Overview
10.9.5 SOM Biotech Recent Developments
10.10 Johnson and Johnson Services, Inc.
10.10.1 Johnson and Johnson Services, Inc. Basic Information
10.10.2 Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.10.3 Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.10.4 Johnson and Johnson Services, Inc. Business Overview
10.10.5 Johnson and Johnson Services, Inc. Recent Developments
10.11 AstraZeneca
10.11.1 AstraZeneca Basic Information
10.11.2 AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.11.3 AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.11.4 AstraZeneca Business Overview
10.11.5 AstraZeneca Recent Developments
10.12 Astellas Pharma, Inc.
10.12.1 Astellas Pharma, Inc. Basic Information
10.12.2 Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.12.3 Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.12.4 Astellas Pharma, Inc. Business Overview
10.12.5 Astellas Pharma, Inc. Recent Developments
10.13 BridgeBio Pharma, Inc.
10.13.1 BridgeBio Pharma, Inc. Basic Information
10.13.2 BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.13.3 BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.13.4 BridgeBio Pharma, Inc. Business Overview
10.13.5 BridgeBio Pharma, Inc. Recent Developments
10.14 Bristol-Myers Squibb Company
10.14.1 Bristol-Myers Squibb Company Basic Information
10.14.2 Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.14.3 Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.14.4 Bristol-Myers Squibb Company Business Overview
10.14.5 Bristol-Myers Squibb Company Recent Developments
10.15 Acrotech Biopharma
10.15.1 Acrotech Biopharma Basic Information
10.15.2 Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.15.3 Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.15.4 Acrotech Biopharma Business Overview
10.15.5 Acrotech Biopharma Recent Developments
11 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET FORECAST BY REGION
11.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast
11.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country
11.2.3 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region
11.2.4 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2026-2035)
12.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2026-2035)
12.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Application (2026-2035)
12.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application
12.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
1.2 Key Market Segments
1.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Type
1.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Life Cycle
3.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Manufacturers (2020-2025)
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Manufacturers (2020-2025)
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Competitive Situation and Trends
3.8.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Rate
3.8.2 Global 5 and 10 Largest Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT INDUSTRY CHAIN ANALYSIS
4.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
5.7 ESG Ratings of Leading Companies
6 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2020-2025)
6.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2020-2025)
6.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price by Type (2020-2025)
7 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Sales by Application (2020-2025)
7.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Application (2020-2025)
7.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
8 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SALES BY REGION
8.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region
8.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.3 North America
8.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.5.2 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country
8.6.2 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region
8.7.2 Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET PRODUCTION BY REGION
9.1 Global Production of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Region(2020-2025)
9.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Region (2020-2025)
9.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production
9.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production
9.5.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.5.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (2020-2025)
9.6.1 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.6.2 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (2020-2025)
9.7.1 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Growth Rate (2020-2025)
9.7.2 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Pfizer Inc
10.1.1 Pfizer Inc Basic Information
10.1.2 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.1.4 Pfizer Inc Business Overview
10.1.5 Pfizer Inc SWOT Analysis
10.1.6 Pfizer Inc Recent Developments
10.2 GlaxoSmithKline Plc
10.2.1 GlaxoSmithKline Plc Basic Information
10.2.2 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.2.4 GlaxoSmithKline Plc Business Overview
10.2.5 GlaxoSmithKline Plc SWOT Analysis
10.2.6 GlaxoSmithKline Plc Recent Developments
10.3 Eidos Therapeutics
10.3.1 Eidos Therapeutics Basic Information
10.3.2 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.3.4 Eidos Therapeutics Business Overview
10.3.5 Eidos Therapeutics SWOT Analysis
10.3.6 Eidos Therapeutics Recent Developments
10.4 Ionis Pharmaceuticals, Inc
10.4.1 Ionis Pharmaceuticals, Inc Basic Information
10.4.2 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.4.4 Ionis Pharmaceuticals, Inc Business Overview
10.4.5 Ionis Pharmaceuticals, Inc Recent Developments
10.5 Alnylam Pharmaceuticals
10.5.1 Alnylam Pharmaceuticals Basic Information
10.5.2 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.5.4 Alnylam Pharmaceuticals Business Overview
10.5.5 Alnylam Pharmaceuticals Recent Developments
10.6 Prothena Corporation Plc
10.6.1 Prothena Corporation Plc Basic Information
10.6.2 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.6.4 Prothena Corporation Plc Business Overview
10.6.5 Prothena Corporation Plc Recent Developments
10.7 Intellia Therapeutics, Inc
10.7.1 Intellia Therapeutics, Inc Basic Information
10.7.2 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.7.4 Intellia Therapeutics, Inc Business Overview
10.7.5 Intellia Therapeutics, Inc Recent Developments
10.8 Corino Therapeutics, Inc
10.8.1 Corino Therapeutics, Inc Basic Information
10.8.2 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.8.4 Corino Therapeutics, Inc Business Overview
10.8.5 Corino Therapeutics, Inc Recent Developments
10.9 SOM Biotech
10.9.1 SOM Biotech Basic Information
10.9.2 SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.9.3 SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.9.4 SOM Biotech Business Overview
10.9.5 SOM Biotech Recent Developments
10.10 Johnson and Johnson Services, Inc.
10.10.1 Johnson and Johnson Services, Inc. Basic Information
10.10.2 Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.10.3 Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.10.4 Johnson and Johnson Services, Inc. Business Overview
10.10.5 Johnson and Johnson Services, Inc. Recent Developments
10.11 AstraZeneca
10.11.1 AstraZeneca Basic Information
10.11.2 AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.11.3 AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.11.4 AstraZeneca Business Overview
10.11.5 AstraZeneca Recent Developments
10.12 Astellas Pharma, Inc.
10.12.1 Astellas Pharma, Inc. Basic Information
10.12.2 Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.12.3 Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.12.4 Astellas Pharma, Inc. Business Overview
10.12.5 Astellas Pharma, Inc. Recent Developments
10.13 BridgeBio Pharma, Inc.
10.13.1 BridgeBio Pharma, Inc. Basic Information
10.13.2 BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.13.3 BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.13.4 BridgeBio Pharma, Inc. Business Overview
10.13.5 BridgeBio Pharma, Inc. Recent Developments
10.14 Bristol-Myers Squibb Company
10.14.1 Bristol-Myers Squibb Company Basic Information
10.14.2 Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.14.3 Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.14.4 Bristol-Myers Squibb Company Business Overview
10.14.5 Bristol-Myers Squibb Company Recent Developments
10.15 Acrotech Biopharma
10.15.1 Acrotech Biopharma Basic Information
10.15.2 Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
10.15.3 Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance
10.15.4 Acrotech Biopharma Business Overview
10.15.5 Acrotech Biopharma Recent Developments
11 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET FORECAST BY REGION
11.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast
11.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country
11.2.3 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region
11.2.4 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2026-2035)
12.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2026-2035)
12.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Application (2026-2035)
12.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application
12.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (M USD)
Table 4. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
Table 5. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Comparison by Region (M USD)
Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2025)
Table 11. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Type (K Units)
Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (M USD)
Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Type (2020-2025)
Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2020-2025)
Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Type (2020-2025)
Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2020-2025)
Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price (USD/Unit) by Type (2020-2025)
Table 33. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Application
Table 34. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
Table 35. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Application (2020-2025) & (K Units)
Table 36. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2020-2025)
Table 37. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2020-2025) & (M USD)
Table 38. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2020-2025)
Table 39. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
Table 40. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 41. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2020-2025)
Table 42. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 43. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025)
Table 44. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 45. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 47. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 50. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 51. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 54. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) by Region(2020-2025)
Table 55. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Region (2020-2025)
Table 57. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Pfizer Inc Basic Information
Table 63. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 64. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Pfizer Inc Business Overview
Table 66. Pfizer Inc SWOT Analysis
Table 67. Pfizer Inc Recent Developments
Table 68. GlaxoSmithKline Plc Basic Information
Table 69. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. GlaxoSmithKline Plc Business Overview
Table 72. GlaxoSmithKline Plc SWOT Analysis
Table 73. GlaxoSmithKline Plc Recent Developments
Table 74. Eidos Therapeutics Basic Information
Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 76. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Eidos Therapeutics Business Overview
Table 78. Eidos Therapeutics SWOT Analysis
Table 79. Eidos Therapeutics Recent Developments
Table 80. Ionis Pharmaceuticals, Inc Basic Information
Table 81. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 82. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Ionis Pharmaceuticals, Inc Business Overview
Table 84. Ionis Pharmaceuticals, Inc Recent Developments
Table 85. Alnylam Pharmaceuticals Basic Information
Table 86. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 87. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Alnylam Pharmaceuticals Business Overview
Table 89. Alnylam Pharmaceuticals Recent Developments
Table 90. Prothena Corporation Plc Basic Information
Table 91. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 92. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Prothena Corporation Plc Business Overview
Table 94. Prothena Corporation Plc Recent Developments
Table 95. Intellia Therapeutics, Inc Basic Information
Table 96. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 97. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Intellia Therapeutics, Inc Business Overview
Table 99. Intellia Therapeutics, Inc Recent Developments
Table 100. Corino Therapeutics, Inc Basic Information
Table 101. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 102. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Corino Therapeutics, Inc Business Overview
Table 104. Corino Therapeutics, Inc Recent Developments
Table 105. SOM Biotech Basic Information
Table 106. SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 107. SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. SOM Biotech Business Overview
Table 109. SOM Biotech Recent Developments
Table 110. Johnson and Johnson Services, Inc. Basic Information
Table 111. Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 112. Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Johnson and Johnson Services, Inc. Business Overview
Table 114. Johnson and Johnson Services, Inc. Recent Developments
Table 115. AstraZeneca Basic Information
Table 116. AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 117. AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Recent Developments
Table 120. Astellas Pharma, Inc. Basic Information
Table 121. Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 122. Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Astellas Pharma, Inc. Business Overview
Table 124. Astellas Pharma, Inc. Recent Developments
Table 125. BridgeBio Pharma, Inc. Basic Information
Table 126. BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 127. BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. BridgeBio Pharma, Inc. Business Overview
Table 129. BridgeBio Pharma, Inc. Recent Developments
Table 130. Bristol-Myers Squibb Company Basic Information
Table 131. Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 132. Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Bristol-Myers Squibb Company Business Overview
Table 134. Bristol-Myers Squibb Company Recent Developments
Table 135. Acrotech Biopharma Basic Information
Table 136. Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 137. Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Acrotech Biopharma Business Overview
Table 139. Acrotech Biopharma Recent Developments
Table 140. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2026-2035) & (K Units)
Table 141. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 143. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 145. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2026-2035) & (K Units)
Table 147. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 149. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Type (2026-2035) & (K Units)
Table 153. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price Forecast by Type (2026-2035) & (USD/Unit)
Table 155. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application (2026-2035)
Table 156. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (M USD)
Table 4. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
Table 5. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Comparison by Region (M USD)
Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2025)
Table 11. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Type (K Units)
Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (M USD)
Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Type (2020-2025)
Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2020-2025)
Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Type (2020-2025)
Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2020-2025)
Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price (USD/Unit) by Type (2020-2025)
Table 33. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Application
Table 34. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
Table 35. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Application (2020-2025) & (K Units)
Table 36. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2020-2025)
Table 37. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2020-2025) & (M USD)
Table 38. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2020-2025)
Table 39. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
Table 40. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 41. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2020-2025)
Table 42. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 43. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025)
Table 44. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 45. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 47. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 50. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2020-2025) & (K Units)
Table 51. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025) & (M USD)
Table 54. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) by Region(2020-2025)
Table 55. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Region (2020-2025)
Table 57. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Pfizer Inc Basic Information
Table 63. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 64. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Pfizer Inc Business Overview
Table 66. Pfizer Inc SWOT Analysis
Table 67. Pfizer Inc Recent Developments
Table 68. GlaxoSmithKline Plc Basic Information
Table 69. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. GlaxoSmithKline Plc Business Overview
Table 72. GlaxoSmithKline Plc SWOT Analysis
Table 73. GlaxoSmithKline Plc Recent Developments
Table 74. Eidos Therapeutics Basic Information
Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 76. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Eidos Therapeutics Business Overview
Table 78. Eidos Therapeutics SWOT Analysis
Table 79. Eidos Therapeutics Recent Developments
Table 80. Ionis Pharmaceuticals, Inc Basic Information
Table 81. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 82. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Ionis Pharmaceuticals, Inc Business Overview
Table 84. Ionis Pharmaceuticals, Inc Recent Developments
Table 85. Alnylam Pharmaceuticals Basic Information
Table 86. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 87. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Alnylam Pharmaceuticals Business Overview
Table 89. Alnylam Pharmaceuticals Recent Developments
Table 90. Prothena Corporation Plc Basic Information
Table 91. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 92. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Prothena Corporation Plc Business Overview
Table 94. Prothena Corporation Plc Recent Developments
Table 95. Intellia Therapeutics, Inc Basic Information
Table 96. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 97. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Intellia Therapeutics, Inc Business Overview
Table 99. Intellia Therapeutics, Inc Recent Developments
Table 100. Corino Therapeutics, Inc Basic Information
Table 101. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 102. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Corino Therapeutics, Inc Business Overview
Table 104. Corino Therapeutics, Inc Recent Developments
Table 105. SOM Biotech Basic Information
Table 106. SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 107. SOM Biotech Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. SOM Biotech Business Overview
Table 109. SOM Biotech Recent Developments
Table 110. Johnson and Johnson Services, Inc. Basic Information
Table 111. Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 112. Johnson and Johnson Services, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Johnson and Johnson Services, Inc. Business Overview
Table 114. Johnson and Johnson Services, Inc. Recent Developments
Table 115. AstraZeneca Basic Information
Table 116. AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 117. AstraZeneca Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Recent Developments
Table 120. Astellas Pharma, Inc. Basic Information
Table 121. Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 122. Astellas Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Astellas Pharma, Inc. Business Overview
Table 124. Astellas Pharma, Inc. Recent Developments
Table 125. BridgeBio Pharma, Inc. Basic Information
Table 126. BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 127. BridgeBio Pharma, Inc. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. BridgeBio Pharma, Inc. Business Overview
Table 129. BridgeBio Pharma, Inc. Recent Developments
Table 130. Bristol-Myers Squibb Company Basic Information
Table 131. Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 132. Bristol-Myers Squibb Company Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Bristol-Myers Squibb Company Business Overview
Table 134. Bristol-Myers Squibb Company Recent Developments
Table 135. Acrotech Biopharma Basic Information
Table 136. Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview
Table 137. Acrotech Biopharma Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Acrotech Biopharma Business Overview
Table 139. Acrotech Biopharma Recent Developments
Table 140. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2026-2035) & (K Units)
Table 141. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 143. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 145. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2026-2035) & (K Units)
Table 147. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (K Units)
Table 149. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Type (2026-2035) & (K Units)
Table 153. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price Forecast by Type (2026-2035) & (USD/Unit)
Table 155. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application (2026-2035)
Table 156. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD), 2025-2035
Figure 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) (2020-2035)
Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Life Cycle
Figure 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Share by Manufacturers in 2025
Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers in 2025
Figure 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2025
Figure 18. Industry Chain Map of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
Figure 19. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market PEST Analysis
Figure 20. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type
Figure 27. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2020-2025)
Figure 28. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type in 2025
Figure 29. Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2020-2025)
Figure 30. Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application
Figure 33. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2020-2025)
Figure 34. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application in 2025
Figure 35. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2020-2025)
Figure 36. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application in 2025
Figure 37. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
Figure 38. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2020-2025)
Figure 39. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025)
Figure 40. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 43. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 45. U.S. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 53. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 55. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2024
Figure 67. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region in 2024
Figure 68. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 79. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 80. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (M USD)
Figure 81. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 82. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region in 2024
Figure 92. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Market Share by Region (2020-2025)
Figure 103. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 106. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Type (2026-2035)
Figure 111. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Application (2026-2035)
Figure 112. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD), 2025-2035
Figure 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) (2020-2035)
Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Life Cycle
Figure 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Share by Manufacturers in 2025
Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers in 2025
Figure 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2025
Figure 18. Industry Chain Map of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
Figure 19. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market PEST Analysis
Figure 20. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type
Figure 27. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2020-2025)
Figure 28. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type in 2025
Figure 29. Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2020-2025)
Figure 30. Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application
Figure 33. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2020-2025)
Figure 34. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application in 2025
Figure 35. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2020-2025)
Figure 36. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application in 2025
Figure 37. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2020-2025)
Figure 38. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2020-2025)
Figure 39. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2020-2025)
Figure 40. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 43. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 45. U.S. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 53. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 55. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2024
Figure 67. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region in 2024
Figure 68. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 79. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2024
Figure 80. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (M USD)
Figure 81. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country in 2024
Figure 82. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region in 2024
Figure 92. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production Market Share by Region (2020-2025)
Figure 103. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 106. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Type (2026-2035)
Figure 111. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Application (2026-2035)
Figure 112. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Application (2026-2035)
